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Open access under CC BYHistone H2AX is rapidly phosphorylated to become cH2AX after exposure to DNA-damaging agents that
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giving a direct correlation with the number of DSBs. This relationship has made cH2AX an increasingly
utilised endpoint in multiple scientiﬁc ﬁelds since its discovery in 1998. Applications include its use in
pre-clinical drug assessment, as a biomarker of DNA damage and in in vitro mechanistic studies.
Here, we review current in vitro regulatory and non-regulatory genotoxicity assays proposing the
cH2AX assay as a potential complement to the current test battery.
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testing.
 2012 Elsevier Ltd.Open access under CC BY-NC-ND license.Contents1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1076
1.1. Kinetics of phosphorylation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1076
1.2. Rationale for measuring cH2AX . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10762. Current genotoxicity tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1077
2.1. Regulatory assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10772.1.1. Ames test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1077
2.1.2. Mouse lymphoma assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1077
2.1.3. Chromosomal aberration test . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1078
2.1.4. In vitro micronucleus assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10782.2. Non-regulatory assays. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1080
2.2.1. In vitro comet assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1080
2.2.2. GreenScreen . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1080
2.2.3. Yeast DEL assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1080
3. cH2AX as a new genotoxicity assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1081
3.1. Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10814. Assessment of cH2AX as a genotoxicity assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1082
5. Applications of cH2AX as a genotoxicity assay in the evaluation of cigarette smoke . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1083
6. Conclusions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1084
Conflict of interest statement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1084
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1084
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1084o, Group Research and Development, Regents Park Road, Southampton, Hampshire SO15 8TL, United Kingdom. Tel.: +44
(C. Garcia-Canton).
-NC-ND license.
1076 C. Garcia-Canton et al. / Toxicology in Vitro 26 (2012) 1075–10861. Introduction
DNA damage can be caused by products from internal metabo-
lism such as reactive oxygen species, but also by a range of exoge-
nous agents, from energetic radiations such as UV light to
chemicals. There are multiple forms of DNA damage; DNA single-
strand breaks (SSBs), DNA–DNA crosslinks or DNA–protein cross-
links or covalent binding to DNA bases, nucleotide substitution,
DNA frameshifts, double-strand breaks (DSBs), etc. DSBs are one
of the most deleterious lesions since they affect both strands of
the DNA helix. This lesion can lead to cell death by triggering apop-
tosis but if the lesion fails to repair or it is repaired incorrectly, DNA
information can be compromised leading to mutation and ulti-
mately cancer and/or heritable damage (Jeggo and Lobrich, 2007).
Histones are highly conserved proteins which play a role not
only in DNA packing but also in DNA repair and gene regulation.
There are 5 families of histones: 1, 2A, 2B, 3 and 4. Histone 2AX
(H2AX) from the histone 2A family becomes rapidly phosphory-
lated (cH2AX) at serine-139 in response to DSBs (Rogakou et al.,
1998). There are mechanisms that get activated after DNA damage
has occurred to avoid genomic instability; they are known as DNA
damage response (DDR). One of the earliest DDRs is the activation
of cH2AX as a result of a DSB. This response occurs within minutes
of the damage, thus making it a useful marker of DNA damage. The
description of events involved in this activation in mammalian
cells leading to cH2AX and beyond is a complex process that has
been described in detail in previous reviews (Riches et al., 2008;
Paull et al., 2000; Fernandez-Capetillo et al., 2004; Cann and Del-
laire, 2011; Bekker-Jensen and Mailand, 2010; Srivastava et al.,
2009; Svetlova et al., 2010).
Brieﬂy, the earliest responding proteins are those of the phos-
phatidylinositol 3-kinase-like family of kinases (PIKK) including
ataxia telangiectasia-mutated (ATM), ATM- and Rad3-related
(ATR) and the catalytic subunit of DNA-dependent protein kinase
(DNA-PKc). The proteins are activated by DNA damage and are rap-
idly recruited to the site of damaged chromatin. Once there, they
phosphorylate the histone 2AX at serine residue 139 located at
the C-terminal tail resulting in the formation of cH2AX. However,
to date it is still not fully understood how DNA damage is detected
by the cellular machinery. Cann et al. suggested two models. The
ﬁrst postulates that changes in the chromatin structure following
a DSB release topological constraints on the DNA helix that ulti-
mately activate ATM. The second model, however, postulates that
the MRE11-RAD50-NBS1 (MRN) complex in its task of keeping
both ends of the broken DNA together is the critical DSB sensor
but also the initial repair force, recruiting ATM to the site where
it becomes activated (Cann and Dellaire, 2011).
Some investigations with cell lines deﬁcient in DNA-PK and
ATM showed a limited increase in H2AX phosphorylation after
DSB damage (Paull et al., 2000). The roles played by the PI3K en-
zymes are thought to be different depending on toxic stimulus or
cell type (Yan et al., 2011; Riches et al., 2008).
Either way, after the initial cH2AX activation, a positive feed-
back loop is created between cH2AX and the PIKKs for further
DDR. The signal ampliﬁcation acts as a repair signal calling for
the repair systems to move to the location of the damage (Nakam-
ura et al., 2010). Within minutes of the damage occurring, cH2AX
can be detected in high quantities in the areas surrounding the DSB
(Rogakou et al., 1999). These areas are known as nuclear foci and
could extend several megabases of chromatin around the site of
damage (Riches et al., 2008). Multiple studies (Cann and Dellaire,
2011; Xu and Price, 2011) suggest that cH2AX foci formation is
mainly limited to euchromatin considered transcriptionally active
and moderately compacted. Heterochromatin representing the
transcriptionally inactive and highly compacted chromatin could
be inaccessible to phosphorylation or more resistant to DNA dam-age. One could also hypothesise that DNA damage in the hetero-
chromatin does not lead to genomic instability as there is no
active transcription. Therefore, repair resources are not invested.
The formation of nuclear foci in response to DNA DSBs differs
from the formation of the ‘‘apoptotic cH2AX ring’’ (Solier and Pom-
mier, 2009). They demonstrated that cH2AX ring staining is an
early apoptosis indicator that precedes a global nuclear staining
or pan-nuclear staining and apoptotic body formation. The main
driver of this particular phosphorylation is DNA-PK in contrast to
ATM and ATR associated with cH2AX nuclear focus formation. This
morphology variation could potentially be used to discriminate
DNA DSBs from other forms of DNA damage.
cH2AX could also act as a cell cycle checkpoint (Downey and
Durocher, 2006). H2AX could become phosphorylated at any point
during the cell cycle, including during mitosis while other DDR
proteins are limited to interphase cells (Nakamura et al., 2010). It
has been suggested that DSB repair mechanisms may be suspended
during mitosis. However, cH2AX foci continue to form during
mitosis. The foci act as indicators to activate the repair mecha-
nisms as soon as the cell has ﬁnished the division process. If the
DNA DSB occurs in G1, the cell cycle would stop to prevent the cell
moving into S-phase with damaged DNA. Likewise, DNA replica-
tion could be slowed if the DNA DSB has occurred in S-phase, so
that the repair mechanisms could act before the DNA polymerase
reaches the damaged section. Finally, when the damage occurs in
G2-phase, the cell is prevented from moving into mitosis, avoiding
the fracture of chromosomes during anaphase and cytokinesis
(Jackson, 2002).
1.1. Kinetics of phosphorylation
Following the induction of DSBs, phosphorylation of the serine
139 residue starts within minutes, reaching a plateau at around
30 min after damage occurs (Paull et al., 2000). The phosphoryla-
tion then decreases over a period of hours (Rogakou et al., 1998).
The mechanism of cH2AX elimination has not been fully unrav-
elled. There are multiple phosphatases involved in cH2AX dephos-
phorylation. Dephosphorylation could occur directly on the
chromatin or could happen after the histone has been displaced
from the nucleosomes (Chowdhury et al., 2005; Redon et al.,
2011a). Both mechanisms could potentially occur simultaneously,
independent of the location of the cH2AX in the foci. Other mech-
anisms mentioned by Bao involve histone chaperone proteins in
the process of cH2AX elimination (Bao, 2011). Experiments carried
out by Keogh and colleagues suggest that the loss of cH2AX could
be triggered not only by DSB repair but also by the activation of
steps that precede DSB repair (Keogh et al., 2006). However, some
of their results seem to indicate that cH2AX loss is not mediated by
single-stranded DNA resection, one of the cellular responses to
DSBs.
1.2. Rationale for measuring cH2AX
There are several reasons why cH2AX is used to detect DSBs.
The formation of cH2AX is proportional to the amount of DSBs, giv-
ing a direct 1:1 correlation to existing damage (Sedelnikova et al.,
2002). This correlation indicates that for every DSB one nuclear fo-
cus would be created. Moreover, H2AX is distributed throughout
the mammalian chromatin and when it becomes phosphorylated
it covers a large area of the chromatin producing the easily detect-
able nuclear foci (Rogakou et al., 1999). The foci can be measured
by different techniques in what is known as the cH2AX assay to
give an account of the DSBs. In addition, this marker is conserved
across eukaryotic evolution, giving the cH2AX assay potential
use not only in human studies but also in other organisms includ-
ing plants (Redon et al., 2011b).
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damage as their endpoint e.g. mutations in the Ames test (OECD,
1997a) or chromosome damage in the in vitro micronucleus test
(OECD, 2010). However, measuring total DNA damage could pro-
vide a complement to the current tests. In general, DNA damage
could produce genome instability or cell death. Mis-repaired
DNA damage could lead to mutation and unrepaired DNA damage
to chromosome breaks. Moreover, repeat DNA damage could satu-
rate the cell repair system leading to accumulation of unrepaired
lesions. The cH2AX assay can provide an indication of DNA damage
which can be used as a pre-screening tool or as a complement to
the standard battery of genotoxicity tests (Watters et al., 2009).2. Current genotoxicity tests
2.1. Regulatory assays
From the total number of assays described to measure genotox-
icity in vitro, only a small number are accepted for regulatory pur-
poses. These are deemed acceptable for estimating the genotoxic
risks posed by compounds commercially employed for human
use and thus are required by regulatory authorities. This group in-
cludes the Ames test, mouse lymphoma assay (MLA), the micronu-
cleus and chromosomal aberration tests. These assays have been
extensively validated and are accompanied by an Organisation
for Economic Co-operation and Development (OECD) guideline
describing the proper conduct of these tests. There is a wealth of
literature available on each of these genotoxicity assays. Therefore,
this section will only brieﬂy describe each assay, its application
and limitations.
2.1.1. Ames test
The Ames test is a bacterial gene mutation assay widely used for
its simplicity, accuracy and low cost (OECD, 1997a). The assay mea-
sures the number of colonies formed after exposure to the test
chemical. If the bacteria have suffered mutations, the frequency of
colonies would be signiﬁcantly higher than the frequency of colo-
nies in the negative control cultures. This assay detects most tested
genotoxic carcinogens with a high sensitivity. However, the Ames
test sometimes fails to detect genotoxic compounds, primarily
those that cause large DNA deletions or compounds that are non-
DNA reactive (aneugens and carcinogens that have a non-genotoxic
mechanisms). Other carcinogenic compounds that have a speciﬁc
target in mammalian cells such as the cell division spindle appara-
tus or DNA polymerases and topoisomerases can also be misla-
belled by the Ames test. Moreover, compounds such as antibiotics
or bacteriocides cannot be tested adequately in the Ames test as
they are toxic to bacteria per se. Additionally, false positives (i.e.
non-carcinogens detected as mutagens) do occur in the Ames test.
There are a small number of compounds that are Ames positive
mutagens due to their bacterium-speciﬁc metabolism e.g. sodium
azide and some nitro-group containing compounds (Prival, 1983).
The strains of Salmonella typhimurium used in the Ames test
contain different mutations in various histidine synthesis genesTable 1
Salmonella typhimurium strains with mutation gene.
Strain Mutated gene (allele) uvrB pKM101 Mutation
TA97 hisD6610 No Yes Frameshift
TA1537 hisC3076 No No Frameshift
TA98 hisD3052 No Yes Frameshift
TA1538 hisD3052 No No Frameshift
TA100 hisG46 No Yes Base substitution
TA1535 hisG46 No No Base substitution
TA102 hisG428 Yes Yes Base substitution
TA104 hisG428 No Yes Base substitution(Table 1). The mutations carried by the speciﬁc strains prevent
the bacteria from growing in media without histidine. However,
if the test chemical mutates the defective mutation back to func-
tional status (revert initial mutation), the bacteria will acquire
the ability to grow in histidine-free media and form colonies. These
colonies are thus known as revertants (Ames et al., 1975).
All strains except TA102 are missing the uvrB DNA repair gene,
thus removing the main error-free DNA excision repair pathway,
compared to wild-type cells. This will amplify the mutations as
DNA repair, in the absence of excision repair, occurs by error-prone
pathways. TA102 bacteria strain maintains the excision repair sys-
tem to be able to detect DNA cross-linking agents such as mitomy-
cin C. Otherwise compounds with DNA cross-link mechanism of
action will not be detected, as unrepaired cross-links are lethal to
the cell.
In addition, all strains have the mutation known as deep rough
or rfa genotype. This is an alteration of the phenotype, where the
polysaccharide capsule surrounding the cell is no longer present.
Therefore, larger compounds are able to enter through the cell
membrane reaching the bacterial DNA.
Various strains possess the plasmid pKM101 which contains the
operon muc. Enzymes encoded by this operon allow the damaged
DNA to continue its synthesis. The effect of this operon is to ampli-
fy the translation of DNA damage to mutations. The plasmid also
contains a gene coding for resistance to the antibiotic ampicillin.
This ampicillin-resistant property permits the selection of mutants
containing the plasmid.
Alternatively, some Escherichia coli strains can be used to screen
for mutagens. These strains have base change mutations in one of
the tryptophan synthesis operon genes (trpE) instead of the histi-
dine operon genes. Strains with and without the uvrA mutation
are available as are strains with and without the plasmid
pKM101. E. coli WP2 strains are equivalent to TA102 in terms of
types of mutagen detected (including oxidative mutagens). How-
ever, if a cross-linking effect is to be detected, then the E. coli strain
must have an intact excision repair system. The rfa mutation is not
required as E. coli cells are naturally permeable to larger molecules.
Each strain of bacteria used in the Ames test detects a different
spectrum of mutagens. Compounds are usually tested in multiple
bacterial strains to understand the nature of their mutagenicity
and also to broaden the range of mutagens detected (Table 1).
There are two types of mutations, base substitution or frame-
shift point mutations. A base substitution is a type of mutation
where one nucleotide is replaced by another. As a consequence, a
codon that will not code for any amino acid could be produced.
This is also referred to as a nonsense mutation creating a stop co-
don which results in a truncated, incomplete or non-functional
protein, when the relevant mRNA is translated. If the substitution
leads to a codon that codes for a different amino acid then it is
referred to as a missense mutation. Missense mutations do not
always lead to marked protein changes but can give rise to non-
functional proteins. Frameshift mutations are typically caused by
loss or gain of a number of nucleotides that are not evenly divisible
by three. As a result, the whole sequence will be modiﬁed from the
point of mutation as the reading frame or sequence of codons will
be changed. This in turn leads to a completely different translation.
The bacterial mutation assays are normally carried out in the
presence and absence of a surrogate for human liver activity such
as rat liver S9 fraction. Liver S9 is obtained from animals treated
with inducers of P450 enzymes required for phase I metabolism.
Thus, compounds that are innocuous but which have DNA reactive
metabolites can be detected.
2.1.2. Mouse lymphoma assay
The mouse lymphoma L5178Y TK assay (MLA) is a gene muta-
tion assay used to assess the mutagenicity of chemicals (OECD,
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although in this case forward mutations are induced rather than
reverse mutations. The selected mutation will cause the cell to
be resistant to a toxic chemical. Thymidine kinase-competent
(TK+/+ or TK+/) mouse lymphoma cells are treated with test chem-
icals, then the cells are transferred to selective media containing
lethal analogues such as triﬂuorothymidine. Only cells that have
mutated to TK/ survive and form colonies. The loss of this spe-
ciﬁc enzyme does not cause any other deleterious effect to the cell.
However, if the mutation results from an extensive deletion
causing the loss of essential genes, the cell will die and no colonies
will form. There are also genes close to the TK gene that are in-
volved in cell growth, thus a deletion that removes these genes will
result in a slow growing colony. This contrasts with point muta-
tions within the TK gene, where a large mutant colony will be
formed. By measuring the numbers of small mutant colonies that
are induced after exposure to a test chemical, an assessment of
clastogenicity can be obtained, as chromosome damage could
result in deletions. By measuring the number of large mutant
colonies, an estimate of induced point mutations can be obtained.
In addition to the MLA, rodent cell lines such as Chinese ham-
ster V79 cells, and Chinese hamster ovary (CHO) cells have also
been used for mammalian cell mutation assays, measuring muta-
tions in the hypoxanthine–guanine phosphoribosyl transferase
(hprt) gene. Moreover, mutation of the TK gene can also be mea-
sured in the human lymphoblastoid cell line TK6. However, the
MLA test is most commonly used as it detects both aneugens
(non-direct effect on DNA) and clastogens (direct effect on DNA).
The current methodology includes the use of either a plate as-
say in soft agar or a liquid exposure in a 96-well microplate
increasing the throughput. However, the scoring of the colonies
has to be done manually by an operator, adding subjectivity to
the process.
Initially, the MLA assay was conducted using short treatments
of 3–6 h. However, the genotoxicity testing guideline from the
International Conference on Harmonisation (ICH) for the registra-
tion of pharmaceuticals recommended a continuous treatment
(24 h) when there is a negative response in the short treatments
in the absence of S9 (ICH, 2008). The longer treatments allow the
cells to go through 1.5–2 normal cell cycles, ensuring that weak po-
sitive chemicals are readily detectable. Additionally, some evi-
dence suggests that aneugenic compounds can also be detected
with this longer treatment time (Moore et al., 2002). However, Fel-
lows et al. have recently advised against the use of MLA as a rou-
tine test to detect aneugens, as some of their tested compounds
did not generate a positive response, while others only produced
positive results at toxic concentrations (Fellows et al., 2011).
As with the Ames test, the MLA assay can be conducted in the
presence of S9. However, S9 can only be used in the short treat-
ments as it is toxic per se when the cells are exposed for more than
3 h.
2.1.3. Chromosomal aberration test
The in vitro chromosomal aberration test is a cytogenetic assay
that has traditionally been used to evaluate chromosome abnor-
malities and stability after chemical treatment (OECD, 1997b).
The assay evaluates the karyotype in the ﬁrst metaphase after a
short (3–6 h) and long (24 h) treatment with test compounds.
This assay is laborious and requires observational skills to score
the different chromosome aberrations. These include chromosome
and chromatid gaps and breaks and more complex rearrangements
including chromosome fusions to produce dicentric chromosomes
and exchange ﬁgures. Although many of these lesions are lethal to
the cell, they are surrogates for stable chromosomal exchanges and
translocations which are compatible with cell survival and are
important in activation of oncogenes and, in some cases, deletionof tumour suppressor genes. The development of ﬂuorescence
in situ hybridization (FISH) has facilitated the identiﬁcation of
chromosome abnormalities.
The in vitro chromosomal aberration test focuses primarily on
structural aberrations. For this reason, carcinogens with a non-
genotoxic potential will not be identiﬁed. Several cell types have
been used routinely for these studies including human peripheral
lymphocytes as well as various established Chinese hamster cell
lines such as V79, CHO and CHL cells.
This assay can include an exogenous source of metabolic activa-
tion such as S9 for use with the shorter exposures.
This test is not easily automated and the throughput is limited.
However, there is imaging technology available to ﬁnd and sort
well spread metaphases for scoring, which signiﬁcantly decreases
the time needed to score experiments. Although an option in the
international guidelines for genotoxicity testing, in general, this as-
say is beginning to be superceded by the in vitromicronucleus test,
which has the advantage of detecting aneugens as well as clasto-
gens more easily (Lynch and Parry, 1993).
2.1.4. In vitro micronucleus assay
The in vitro micronucleus assay is a cytogenetic test that mea-
sures genetic damage using the formation of micronuclei as an
endpoint (OECD, 2010). Micronuclei are small membrane-bound
structures that contain chromosome fragments or sometimes
whole chromosomes that are not incorporated into either daughter
nucleus. The majority of micronuclei contain DNA fragments giving
a measure of chromosomal damage or clastogeniticy. The content
of the micronuclei can be identiﬁed by adding an extra step in
the standard method: Centromere immunostaining gives this assay
the ability to identify aneuploidy when the micronucleus contains
a whole chromosome (Lynch and Parry, 1993).
The micronuclei should be present in cells that have undergone
at least one mitosis. Segregating the populations that have experi-
encedmitosis was initially a challenge. This led to the development
by Fenech of the cytokinesis-blocked micronucleus assay (CBMN)
which uses cytochalasin B to inhibit membrane division after mito-
sis (karyokinesis) (Fenech, 2007). This allows the scorer to identify
which cells have undergone mitosis by counting the micronuclei
present in binucleated cells (cells containing both daughter nuclei).
The micronucleus test shows ﬁxed DNA damage in the form of
chromosomal breaks or chromosomal loss but does not give an
indication of total damage as some of the initial damage can be re-
paired or the cell can undergo apoptosis. The micronucleus test
does not detect point mutations. For this reason, a mutation assay
is always needed as a complementary test in genotoxicity test
batteries.
This assay can be performed in the presence of S9 to detect pro-
mutagens. However, S9 is only employed for the short treatments
as it is toxic per se to mammalian cells in culture.
The technique involved in this assay is much simpler than the
chromosomal aberration test where the analysts require greater
skills to prepare the metaphases and score the aberrations. How-
ever, a degree of subjectivity is associated with the manual scoring
which also limits the throughput. Over the past few years, some
automation methods for scoring micronuclei have gained accep-
tance, in particular ﬂow cytometry (Lynch et al., 2011).
In a recent review, Dearﬁeld et al. compiled a list of all available
genotoxicity assays and organised them into 4 categories based on
their validation status, strengths and weaknesses (Dearﬁeld et al.,
2011). Table 2 above details the assays contained in their ‘‘category
one’’ also known as regulatory assays comprising of assays that are
well-characterised and have an issued OECD guideline and are cur-
rently used for regulatory purposes.
The Ames test is considered to have high speciﬁcity, with a low
frequency of false positive results with non-carcinogens. However,
Table 2
In vitro genotoxicity regulatory assay. Adapted from (Dearﬁeld et al., 2011).
Assay Endpoint Strengths Limitations Opportunities
Ames bacterial
reverse
mutation
assay
Gene mutations (point mutations
including base pair substitutions
and frameshift mutations) in
bacterial cells
Commonly used, well validated,
inexpensive, recognised
guideline, ability to
differentiate frameshift and
point mutations (different
bacterial strains).
Can be conducted both with
and without metabolic
activation
Prokaryotic (bacterial speciﬁc);
does not detect clastogens
Use as high throughput
screening test. (Jacobson-Kram
and Contrera, 2007)
In vitro mouse
lymphoma
L5178Y tk+/
assay
Gene mutations (point mutations
including base pair substitutions
and frameshift mutations) in
mammalian cells. Can also detect
various sizes of chromosome
deletions, mitotic recombination,
chromosome rearrangements, and
some aneugens
Can detect point mutation
inducers, clastogens and some
aneugens.
Can be conducted both with
and without metabolic
activation
Use of positive controls for colony
sizing essential for quality control.
Colony sizing required to
distinguish between point
mutation or clastogen endpoints.
Evaluation and interpretation
changed over the years. Recent
protocol updates recommended.
Cytotoxicity (necrosis and
apoptosis) needs to be controlled
to avoid false positive results
Recent protocol updates
recommended (adjusted relative
total growth and global
evaluation factor), might
improve data interpretation.
(Moore et al., 2002; Moore et al.,
2007)
In vitro gene
mutation assay
in mammalian
cells
(excluding
mouse
lymphoma
assay)
Gene mutations (point mutations
including base pair substitutions
and frameshift mutations) in
mammalian cells (e.g. hprt). Can
also detect various sizes of
chromosome deletions when
autosomal gene (e.g., in AS52 cells)
is used; hprt locus assay can detect
some deletions, though not very
efﬁciently
Detects gene mutation in
mammalian cells without
confounding chromosome
damage when non-autosomal
genes are used.
Can be conducted both with
and without metabolic
activation
Currently infrequently used but may
be used more in future (e.g. REACH,
interest in in vitro alternatives to
in vivo testing).
Chinese hamster cells considered by
some to be insufﬁciently sensitive.
Cytotoxicity (necrosis and
apoptosis) needs to be controlled to
avoid false positive results
mammalian cells
For AS52 cell lines, can be used
as alternative to metaphase
analysis
In vitro
chromosome
aberration
assay
Structural and numerical
chromosome damage in
mammalian cells (i.e.,
clastogenicity and polyploidy)
Detects clastogens and
polyploidy inducers, including
some aneugens.
Some information on
aneugenicity can be obtained
with extended culture times.
Applicable to different cell
types, able to proliferate in
culture. Provides information
on the type of chromosome
aberrations.
Analysis made on individual
cells.
Can be conducted both with
and without metabolic
activation
Resource intensive and time
consuming scoring of aberrations.
Requires skilled scientists.
Polyploidy provides suboptimal
predictivity of aneugenicity. Limited
number of cells evaluated.
Cytotoxicity (necrosis and
apoptosis) needs to be controlled to
avoid false positive results
FISH/chromosome painting can
provide additional mechanistic
information
In vitro
micronucleus
assay
Structural and numerical
chromosome damage in
mammalian cells (i.e.,
clastogenicity and aneuploidy)
Can detect both aneugens and
clastogens.
Rapid and easy to conduct.
Applicable to different cell
types that can proliferate in
culture. Analysis made on
individual cells.
Can be conducted both with
and without metabolic
activation
Resource intensive and time
consuming scoring of micronuclei.
Does not distinguish complex
rearrangements and chromosome
breaks.
Cytotoxicity (necrosis and
apoptosis) needs to be controlled to
avoid false positive results
Mechanistic studies: can be used
with and without FISH analysis
of centromeres to differentiate
clastogens from aneugens. Can
be used for screening assay.
Potential for automation, e.g.
ﬂow cytometry, image analysis.
(Kirsch-Volders et al., 2011)
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activity with eukaryotic cells. Additionally, compounds such as
antibiotics or bacteriocides cannot be tested adequately in the
Ames test as they are toxic to bacteria per se. False positives (i.e.
non-carcinogens detected as mutagens) do occur in the Ames test.
Those include compounds with bacterial-speciﬁc metabolism (e.g.
sodium azide) and some nitro-group containing compounds which
will not produce a harmful effect in mammalian cells. Therefore,
in vitro mammalian assays are required to generate a complete
safety assessment of genotoxicity potential (Kirkland et al., 2007a).
Unfortunately, the established in vitro mammalian cell tests
produce an unacceptable rate of false positives (Kirkland et al.,
2007b). For this reason they are deﬁned as low speciﬁcity assays,and several causes are thought to be responsible for this lack of
speciﬁcity. Many of the cell systems used for these assays are deﬁ-
cient in DNA repair mechanisms. In addition, genetic drift occur-
ring during repeated subculturing can make them artiﬁcially
prone to genetic damage. The high rates of false positives are also
increased by the current guidelines requiring very high test con-
centrations of up to 10 mM or 5000 lg/mL. Furthermore, guide-
lines require top concentrations to elicit high levels of
cytotoxicity of 50% or even higher (90% for the MLA). These condi-
tions can result in the appearance of genetic damage that is unre-
lated to the inherent genotoxicity of the test compounds
themselves. Moreover, the use of different cytotoxicity measures
such as relative cell counts (RCC), relative population doubling
1080 C. Garcia-Canton et al. / Toxicology in Vitro 26 (2012) 1075–1086(RPD), and mitotic index (MI) among others, could lead to different
cytotoxicity results (Kirkland et al., 2007b; Greenwood et al.,
2004). Kirkland showed that, by using different cytotoxicity mea-
sures, the same compound could give a positive or negative re-
sponse at the maximum level of toxicity (50%) in the in vitro
micronucleus test (Kirkland, 2010).
Finally, the in vitro assays only have the inherent ability to de-
tect mutagens and carcinogens but they cannot detect the metab-
olites produced by hepatic metabolism from compounds known as
promutagens or procarcinogens. To cover this deﬁciency, the
majority of the assays require an exogenous metabolic source, such
as rat liver S9 fraction from animals treated with inducers of P450
enzymes. However, S9 is deﬁcient in detoxiﬁcation phase II en-
zymes (and no co-factors for these enzymes are included in the
S9 mix) giving rise to a high level of metabolites which may be
irrelevant to in vivo systems. Alternatively, some mammalian cell
tests can use genetically modiﬁed cell lines with some degree of
metabolic capability like engineered Chinese hamster V79 cells
or can be co-cultured with primary hepatocytes (Kirkland et al.,
2007b; Pfuhler et al., 2011; Dearﬁeld et al., 2011).
2.2. Non-regulatory assays
The current mammalian in vitro genotoxicity assays have a high
rate of positive results that do not translate into positive rodent
carcinogenicity results. This raises the concern that these in vitro
assays are overly sensitive and therefore generate false positives
(Dearﬁeld et al., 2011; Kirkland et al., 2007b). Some companies
use non-regulatory assays as early screening tools (Jacobson-Kram
and Contrera, 2007).
Recently, Lynch et al. have reviewed the status of new and
emerging technologies, comparing them with the current battery
of genotoxicity tests (Lynch et al., 2011). These tests do not yet
have an accompanying OECD guideline, or not enough data has
been collected to fully establish them (trials, validations). This
group of assays includes, for example, the comet assay, Green-
Screen assay and the cH2AX detection assay. These assays are clas-
siﬁed as replacements or improvements of the traditional
genotoxicity assays, forming a new approach to replace traditional
assays or providing mechanistic understanding complementary to
the traditional assays. Subcategories to classify these assays have
been deﬁned by experts in the ﬁeld and are described as mature,
maturing and emerging (Lynch et al., 2011).
Mature refers to methods or technologies that have been in the
ﬁeld for a relatively long time and are amongst those tests that are
likely to become accepted in the foreseeable future. However,
these are still not yet fully accepted by regulatory bodies. One rea-
son for this lack of acceptance is the need for generating more data
by comprehensive validation exercises. This category includes, for
example, the comet assay, and in silico technologies for genotoxi-
city prediction based on chemical structure–activity relationships
(SARs) etc.
Maturing refers to those methods or technologies that have
proved to add value to the existing methods but have not yet gone
through an extensive validation exercise. Maturing assays are the
novel GreenScreen assay and yeast DEL assay. Additionally, this
category also encompasses the automation of existing methods
such as, for example, the development of ﬂow cytometry to score
in vitro micronucleus samples.
Emerging refers to new technologies that are currently in
development, i.e. they show interesting capabilities but require
further testing/development. While the standard battery of geno-
toxicity assays looks at gene mutation or chromosomal damage
and variation in chromosome numbers (aneugenicity), there are
a number of promising new genotoxicity endpoints of interest
related to DNA repair-related protein modiﬁcation as a responseto DNA damage, such as the histone phosphorylation to form
cH2AX, subject of this paper. Other genotoxicity approaches clas-
siﬁed as emerging technologies are toxicogenomics, the use of
humanised cell lines and Pig-a gene mutation assay among oth-
ers (Lynch et al., 2011).2.2.1. In vitro comet assay
The in vitro comet assay or single cell gel electrophoresis assay
is currently considered as a mature technology (Lynch et al., 2011).
The assay detects DNA damage in individual cells. The methodol-
ogy employs a microgel electrophoresis technique at alkaline pH
(pH > 13). The measurements of the comet tails (DNA migration)
after the cells are lysed gives an indication of the amount of DNA
damage present in the cells (Tice et al., 2000; Kumaravel and Jha,
2006). It is a very sensitive assay. However, in the past the comet
assay has shown a high variability caused mainly by physical fac-
tors such as temperature, and materials that generate variation
not only in inter-laboratory but also in intra-laboratory compari-
sons. At this point, the method is still not fully optimised or vali-
dated, however, further research is still ongoing (Zainol et al.,
2009).
The comet assay can take advantage of existing software to
score the comets. However, its throughput is limited. This assay
does not require cell division. Therefore, a parallel assessment of
the compound cytotoxicity would be needed to ensure the DNA
damage is not caused by high toxicity (Dearﬁeld et al., 2011).
This assay can use any eukaryotic cell or tissue and it has the
versatility to be used in vitro and in vivo where it may be included
in tests being carried out for other purposes such as a repeat dose
general toxicology study.
The addition of an external source of metabolic activation in the
in vitro comet assay is possible if the selected cell system is not
metabolically competent.2.2.2. GreenScreen
The GreenScreen assay, considered to be a maturing assay, is a
completely new approach to genotoxicity evaluation. It uses the
transcriptional response of the human GADD45a gene as a marker
of genotoxic stress. The gene for green ﬂuorescent protein (GFP) is
fused to the GADD45a promoter allowing a ﬂuorescent signal to be
generated when the GADD45a gene is induced following exposure
to genotoxins. The host cell line is the human lymphoblastoid line
TK6, which has the advantage of being p53-competent. This com-
petency allows the cells to maintain genomic stability after geno-
toxic stress reducing the rate of false positives (Kirkland et al.,
2007b; Lynch et al., 2011).
This assay has initially been developed without the use of rat li-
ver S9 in a multi-well microplate format, which allowed for a rea-
sonable throughput in use (Hastwell et al., 2006). After the initial
development, it was further modiﬁed to include the use of S9 with
ﬂow cytometry scoring (Jagger et al., 2009), although this resulted
in a lower throughput.2.2.3. Yeast DEL assay
The Yeast DEL assay is another new approach to genotoxicity
evaluation and is also classiﬁed as a maturing assay. The assay uses
homologous recombination scoring for DNA deletion in the yeast
Saccharomyces cerevisiae. The assay can detect carcinogens that
act directly on the DNA (clastogens) (Kirpnick et al., 2005). The
methodology has been modiﬁed to support microwell plate use
thereby increasing throughput (Hafer et al., 2010). However, there
are still concerns about the cell wall permeability of the yeast and
the perceived relevance of the cell system (Lynch et al., 2011).
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There are 2 major limitations to the current in vitromammalian
genotoxicity assays:
Low throughput: this is mainly linked to the manual scoring that
limits large scale screening in terms of time. In the last few
years, some technologies have been developed to increase the
throughput. For example, automated ﬂow cytometric analysis
is used to score in vitro micronucleus samples (Bryce et al.,
2007). This methodology could potentially be used as a pre-
screening tool while awaiting further validation, as detailed in
a recent review (Avlasevich et al., 2011).
High frequency of false positives: a large proportion of non-car-
cinogenic compounds produced positive results in at least one
of the in vitro assays of the standard battery of genotoxicity
tests (Kirkland et al., 2007b). The relevance of those in vitro pos-
itives was not conﬁrmed in the follow-up in vivo genotoxicity
tests. This contributes to delays in drug development and an
increase in animal use. Moreover, for the cosmetic industry,
where animal testing is banned by the EU 7th Amendment
Directive (European Commission, 2003), the effect of a false
positive has serious consequences in potential loss of useful
compounds.
3.1. Methods
The cH2AX assay could be of potential use in overcoming the 2
major limitations mentioned above. There are several methods for
detecting cH2AX and these have evolved to become simpler,
quicker and more automated.
Initially, cH2AX detection employed acetic acid-urea-triton and
acid-urea-cetyltrimethylammonium bromide polyacrylamide gel
electrophoresis (aut-aucPAGE), a two-dimensional gel analysis to
detect the level of phosphorylated H2AX. Gels from untreated
mammalian cell cultures were compared to gels generated using
radiated cultures. The gels from the treated cells showed an addi-
tional shadowed area identiﬁed as a region containing the cH2AX
protein which migrates through the gel differently than non-
phosphorylated H2AX (Rogakou et al., 1998).
However, after the initial development of this approach, immu-
nocytochemical detection as described by Rogakou et al. became19
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Fig. 1. (A) Since its discovery as a DNA DSB marker in 1998 (arrow), the number of publi
updated from (Dickey et al., 2009). (B) Areas in which cH2AX is studied as a marker ofthe primary method of detection, as it is several orders of magni-
tude more sensitive and has the potential for quantitation (Roga-
kou et al., 1999), (Sedelnikova et al., 2002). This method is based
on the use of a cH2AX-speciﬁc monoclonal ﬂuorophore-coupled
antibody. Once cH2AX presence has been detected by the antibody
based technique, the results can be quantiﬁed using various
methods. These approaches have been discussed extensively in a
previous review (Bonner et al., 2008) and are summarised brieﬂy
below:
Immunoﬂuorescence analysis: a phosphospeciﬁc antibody is
used to detect cH2AX, the antibody does not bind to any non-phos-
phorylated H2AX. This antibody can either be directly labelled with
a ﬂuorophore reporter or detected by addition of a secondary,
ﬂuorophore-labelled antibody. The stained cH2AX can then be
analysed by manual or automated scoring.
– Manual scoring: the stained cells are evaluated by eye using a
ﬂuorescence microscope. This method will only be able to give
qualitative results, i.e. presence or absence of ﬂuorescence.
Additionally, the number of foci per cell could be counted. This
scoring method is considered very time consuming and has a
high level of subjectivity (Sedelnikova et al., 2002).
– Automated detection using a cell enzyme-linked immunosor-
bent assay (cell-ELISA): a peroxidase-conjugated secondary
antibody substitutes the standard ﬂuorophore-conjugated sec-
ondary antibody used in immunocytochemistry. The enzy-
matic reaction carried out by the peroxidase generates an
amount of product that can be measured by absorbance. This
absorbance measure would be directly proportional to the
amount of cH2AX present in the cells. This methodology has
the advantage of high throughput technology. However, no
measure of focus number per cell or distribution would be
available (Matsuzaki et al., 2010). A variation of this method
consists of reading the infrared ﬂuorescence dye from the sec-
ondary antibody directly on the microwell plate (Audebert
et al., 2010).
Automated scoring using ﬂow cytometry: the ﬂow cytometer uses
a laser to detect the ﬂuorescence per nucleus. This method will
generate qualitative results based on measures of cH2AX anti-
body present in the sample. However, the cells are destroyed
in the process and no measure of focus number per cell or dis-
tribution is available (Banath and Olive, 2003).cations containing H2AX in the title/abstract has grown exponentially. Adapted and
DNA damage. Taken from (Redon et al., 2011b).
Table 3
Studies using well-characterised compounds to assess cH2AX as a marker of DNA DSB damage.
Year Detection method Compounds References
2005 Immunoblotting and
Microscopy
Norethindrone Gallmeier et al.
(2005)
2006 Microscopy Methyl methanesulfonate, N-ethyl-N-nitrosourea, benzo(a)pyrene, 2-acetyl-aminoﬂuorene, azathioprine,
cyclosporine A
Zhou et al.
(2006)
2008 Microscopy Bleomycin Rakiman et al.
(2008)
2008 Flow cytometry Etoposide and mitoxantrone Smart et al.
(2008)
2009 Flow cytometry Etoposide, methyl methanesulfonate, bleomycin, ampicillin, sodium chloride Watters et al.
(2009)
2010 Microscopy and
immunoblotting*
Benzo(a)pyrene, ﬂuoranthene, 3-methylcholanthrene Audebert et al.
(2010)
2010 Cell-ELISA Methyl methanesulfonate, N-ethyl-N’-nitro-N-nitrosoguanidine, mitomycin C, cis-diamminedichloroplatinum II,
irinotecan hydrochloride hydrate, etoposide, methotrexate hydrate, 5-ﬂuorouracil, colcemid, vincristine sulfate salt,
paclitaxel, griseofulvin, 17-allylaminogeldanamycin, sodium dodecyl sulfate, sodium chloride
Matsuzaki
et al. (2010)
2011 Microscopy Doxorubicin, cisplatin, etoposide, camptothecin, bleomycin Kim et al.
(2011)
2011 Flow cytometry Cyclophosphamide, ethyl methane sulphonate, methyl methane sulphonate, n-butyl chloride, trimethyl ammonium
chloride, 2-acetylaminoﬂuorene, 2-aminoanthracene, 5-chloro-o-toluidine, 2,4-diaminotoluene, p-chloroaniline, 4-
nitroquinolineoxide, p-nitroaniline, mitomycin C, glycidol, 1,2-propylene oxide, styrene oxide, benzo(a)pyrene,
hydrogen peroxide, endrin, methyl nitrosourea, ethyl nitrosourea, dimethylbenz(a)anthracene, hydroquinone,
phenanthrene, isobutyraldehyde, ethyl acrylate, D-mannitol, cyclohexanone, methyl carbamate, hexachloroethane,
phthalic anhydride, resorcinol, propyl gallate, eugenol
Smart et al.
(2011)
⁄
Score in multi-well plate, no gel required.
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itative method uses automatic microscopy to acquire cell
images and image analysis software to measure different end-
points such as brightness, focus number per cell, distribution
etc. This method generates and stores the images for future
re-scan or quality control check (Kim et al., 2011; Hou et al.,
2009).
Immunoblotting analysis: Here absolute amounts of cH2AX
protein aremeasured and compared to the total H2AX andH2A con-
tent. However, different cell types have different cH2AX/H2AX and
H2AX/H2A ratios yielding as a result different absolute amounts
of cH2AX for the same number of DSBs (Rogakou et al., 1998).
Overall, microscopic analysis of cH2AX is considered to be more
sensitive than other methods such as ﬂow cytometry (Kim et al.,
2011). Initial microscopy developments in this area were limited
to manual scoring of the samples which is restrictive in terms of
sample generation (slide vs. microwell plate), operator time and
subjectivity.
New developments in the area of automated microscopy and
image analysis software have increased the sensitivity of the re-
sults obtained by HCS. Additionally, the use of microplates and ro-
botic systems has promoted the development of high throughput
assays. Moreover, the use of software analysis allows objective
quantitative scoring, avoiding operator subjectivity. The potential
for multiplexing or evaluating various endpoints simultaneously
is an attractive option as there would be a reduction in experimen-
tal time and resources. Therefore, from the current methods de-
scribed above, HCS is considered a strong candidate for routine
testing of cH2AX.Fig. 2. Activation of Benzo(a)pyrene (B(a)P) to Benzo(a)pyrene diol-epoxide (BPDE) by a P
DNA-adducts.4. Assessment of cH2AX as a genotoxicity assay
In the last decade, the use of H2AX to assess DNA damage has
grown exponentially as demonstrated by the number of publica-
tions (Fig. 1A). This growth comes as a consequence of the diversi-
ﬁcation of scientiﬁc ﬁelds where H2AX is used (Fig. 1B). Initial
studies were carried out in the ﬁeld of radiation research, but once
the relation between the phosphorylation of H2AX and DSBs was
demonstrated (Rogakou et al., 1998), the use of cH2AX soon ex-
panded to other areas.
The initial methodologies supported experimentation focused
on DNA damage and repair mechanisms (Mukherjee et al., 2006;
Marti et al., 2006; Celeste et al., 2003; Bassing et al., 2003) to men-
tion some. Other studies were orientated to assess the DNA dam-
age potential of drugs, potency of chemotherapy agents and
other medical materials (Tanaka et al., 2006; Ansteinsson et al.,
2011; Olive and Banath, 2009).
Further optimisations in cH2AX detection allowed the use of
this indicator of DSBs as a biomarker (Muslimovic et al., 2008; Cor-
nelissen et al., 2011). For example, Muslimovic et al. used non-
ﬁxed blood cells from irradiation patients to develop a biomarker
that could potentially lead to modulation of radiological treatment
(Muslimovic et al., 2008; Johansson et al., 2011). The clinical use of
cH2AX as a biomarker has been reviewed recently (Redon et al.,
2010).
In the ﬁeld of genetic toxicology, Albino et al. proposed the use
of cH2AX as a novel genotoxicity assay using ﬂow cytometry (Al-
bino et al., 2004) and was soon followed by Gallmeier et al. recom-
mending immunocytochemistry (Gallmeier et al., 2005). Since
then, multiple compounds have been tested in the cH2AX assayhase I enzyme from the cytochrome P450. BPDE binds to the DNA molecule creating
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cH2AX is considered as a good marker of genotoxic damage. More-
over, the large number of compounds tested by Smart et al. has
shown the cH2AX assay to be a sensitive and speciﬁc assay for
the assessment of genotoxicity (Smart et al., 2011).
Some cell systems used in in vitro toxicology testing are re-
ported to have different deﬁciencies in their metabolism leading
to incorrect evaluation of test compounds (Kirkland et al.,
2007a). These limitations could also affect the predictivity of the
cH2AX assay. To prevent this, study designs need to incorporate
a metabolically competent cell system or, alternatively, an exoge-
nous source of metabolic activation to detect protoxicants. These
are compounds that have to be metabolically activated before their
toxic form is active, a prime example being benzo(a)pyrene known
as B(a)P (Fig. 2).
Audebert et al. tested various polycyclic aromatic hydrocarbons
(PAHs), such as B(a)P, in three different cell lines. They demon-
strated that in HepG2, B(a)P can be oxidised and conjugated (Aude-
bert et al., 2010), however, the metabolic competency of HepG2
has some limitations as discussed previously (Jennen et al.,
2010). The use of cell lines with metabolic capabilities has been
previously recommended to improve the speciﬁcity without com-
promising the sensitivity of the method. (Rueff et al., 1996; Kirk-
land et al., 2007b).
An alternative approach to the use of cell lines with full or lim-
ited metabolic competency, is the introduction of an exogenous
source of metabolism during the experimentation. The most com-
monly used is the hepatic S9 fraction or S9, liver microsomes from
rats pre-stimulated with Aroclor1254 or phenobarbital/b-napht-
hoﬂavone. This methodology is currently applied to the entire bat-
tery of regulatory tests, where S9 is added for short treatments
(3 h) due to its toxicity (OECD, 2010, 1997c). The same approach
was followed by Smart et al. where mouse lymphoma L5178Y cells
were used to assess cH2AX induction after exposure to a panel of
protoxicants in the presence of S9 (Smart et al., 2011). Alterna-
tively, other sources of metabolic activation could be employed.
Hepatic human microsomes could be used for a human-speciﬁc
metabolism or a lung subcellular fraction for a more organ-speciﬁc
metabolism. However, incorporating human material could in-
crease the variability compared to the S9 from laboratory animals.
The use of metabolically competent cell systems like HepaRG or
human stem cells has also been discussed as an option to reduce
the false positives produced by the higher activation capacity of
the rat S9 fraction (Kirkland et al., 2007b).5. Applications of cH2AX as a genotoxicity assay in the
evaluation of cigarette smoke
Cigarette smoke is a complex mixture consisting of a particulate
phase and a vapour phase. It is estimated that the whole mixture
contains approximately 5600 compounds (Perfetti and Rodgman,
2011). Over 150 known toxicants are present in tobacco smokeTable 4
Physical forms of cigarette smoke used in in vitro testing. Taken from (Breheny et al., 201
Name Description
Cigarette smoke condensate (CSC) Comprises the particulate phase along with som
smoke at extremely low temperatures. The con
Cigarette smoke total particulate
matter (TPM)
Comprises the particulate phase only. Particula
are subsequently eluted using a solvent such as
Cigarette smoke extract (CSE) Comprises the particulate phase along with som
phosphate-buffered saline or cell culture mediu
Whole mainstream cigarette
smoke (WMCS)
Cells are directly exposed to smoke at the air–li
cells are exposed to the gas and vapour phase c(Cunningham et al., 2011). Some of those compounds are known
carcinogens, such as B(a)P, a PAH and 4-(N-methylnitrosamino)-
1-(3-pyridinyl)-1-butanone (NNK), a tobacco-speciﬁc N-nitrosa-
mine. Both compounds are classiﬁed by IARC as ‘‘carcinogenic to
humans’’ (Group 1) (IARC, 2012a; IARC, 2012b).
Testing of complex mixtures is problematic as a small number
of particular components can mask the effects of others, especially
if they elicit high cytotoxicities. In addition, components can also
act synergistically or act competitively, so the testing of mixtures
can only give a global picture obscured by these factors. Fraction-
ation of the different smoke components can assist in the determi-
nation of what the key toxic drivers in smoke may be. A global
picture can also be used to compare smoke from different tobaccos,
which may have different toxicities.
There are different mechanisms by which cigarette smoke car-
cinogens interact with DNA (Hecht, 1999). DNA adduct formation
and oxidative DNA damage are mechanisms known to generate
DSBs by acting directly on the DNA. Cigarette smoke has also
shown to have aneugenic activity (Van et al., 2008), an indirect-
acting mechanism of genotoxicity. However, no single compound
present in cigarette smoke has been classiﬁed as an aneugenic
compound.
Currently, the genotoxic potential of cigarette smoke is mea-
sured mostly using methods focusing on ﬁxed DNA damage after
acute exposures to different forms of cigarette smoke (DeMarini
et al., 2008; Schramke et al., 2006; Van et al., 2008; Wolz et al.,
2002; Nakayama et al., 1985; Johnson et al., 2009). There are also
multiple clinical studies focusing on the genotoxic effects of ciga-
rette smoke in humans (Hruba et al., 2010; Choudhury et al.,
2008; Mondal et al., 2010). However, these clinical studies fall
out of the scope of this review.
Recent reviews described the different physical forms of ciga-
rette smoke used in in vitro testing (Table 4) and the history of
the collection of tobacco smoke for toxicology testing (Breheny
et al., 2011; Johnson et al., 2009).
De Marini conducted a detailed review of the genotoxicity of to-
bacco smoke and tobacco smoke condensate (DeMarini, 2004).
Overall, cigarette smoke condensate (CSC) and cigarette smoke to-
tal particulate matter (TPM) have been the main testing forms of
cigarette smoke in vitro. The use of CSC or TPM for in vitro genotox-
icity testing has the advantage that test material can be prepared
as a concentrated stock solution in a compatible solvent (usually
DMSO) and applied at a relatively high top concentration in a range
of in vitro test systems, thus maximizing the potential to detect and
quantify a genotoxic effect. Resultant data can be normalized on a
per milligram tar, per cigarette or per milligram nicotine basis,
facilitating product comparisons (DeMarini et al., 2008). However,
it is also clear that such assays cannot assess the contribution that
the vapour phase of cigarette smoke may make toward toxicity.
Moreover, these exposure agents are not fully representative of hu-
man exposure as cells are not fully exposed to both the particulate
and vapour phase components of the cigarette smoke. A number of
whole smoke exposure systems are being developed to address1).
e vapour phase components. Generated by cold-trapping and condensation of
densed ‘tar’ is then typically extracted and diluted using acetone
tes are collected by passing cigarette smoke through a Cambridge ﬁlter pad and
dimethylsulphoxide
e vapour phase components. Generated by bubbling smoke in a liquid (e.g.
m)
quid interface. This is the most representative of human exposure conditions, as
omponents in an aerosol (Phillips et al., 2005)
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dosimetric comparisons can be made and have not yet been vali-
dated. Whole smoke exerts signiﬁcant cytotoxicity and therefore
precise exposure conditions need to be deﬁned in order to detect
speciﬁc genotoxic effects. Of course the real key to deﬁnition of
appropriate smoke exposure systems for toxicity testing is to
understand the contribution of individual tobacco smoke constitu-
ents to the genotoxic effects (both singly and in combination) and
to estimate their concentration in tobacco smoke particulate and
vapour phase fractions. This understanding then facilitates the de-
sign of appropriate tobacco smoke exposure systems, focusing on
key drivers of genotoxicity, facilitating product comparisons and
providing a scientiﬁc rationale for any observed differences in
genotoxic potential.
To date, there are a limited number of studies using whole
mainstream cigarette smoke (WMCS) in in vitro genotoxicity as-
says. WMCS was ﬁrst used as a smoke exposure system in the
in vitro micronucleus assay (Massey et al., 1998; Okuwa et al.,
2010). In addition, Aufderheide et al. developed a WMCS method
to evaluate the mutagenicity of cigarette smoke in various bacte-
rial strains in the Ames test (Aufderheide and Gressmann, 2007;
Aufderheide and Gressmann, 2008). To date, there is no published
information of this exposure system in the MLA assay.
In the ﬁeld of non-regulatory assays, WMCS was used by Thorne
et al. to measure oxidative DNA damage in the in vitro comet assay
(Thorne et al., 2009). Studies to measure the activation of H2AX in
response to DNA damage in vitro after cigarette smoke exposure
have also used CSC, TPM or cigarette smoke extract (CSE) as a
smoke exposure system (Albino et al., 2004, 2006, 2009; Tanaka
et al., 2007a,b; Luo et al., 2004; Zhao et al., 2009; Jorgensen
et al., 2010; Darzynkiewicz et al., 2011).
The in vitro cH2AX assay was originally used to measure DSBs
following cigarette smoke exposure (Albino et al., 2004). Human
A549 pulmonary adenocarcinoma cells were exposed to cigarette
smoke and normal human bronchial epithelial (NHBE) cells to
CSC. Both cell systems showed a dose-related response in cH2AX
activation. Once the relationship between smoke exposure and
cH2AX activation was conﬁrmed, Albino et al. used the assay to
evaluate cigarettes with different tar deliveries. The results indi-
cated that the increment in cH2AX intensity was proportional to
the estimated tar delivery rather than the cigarette type or smok-
ing behaviour (Albino et al., 2009).
Interestingly, when Kato et al. evaluated the response of CSC in
the commonly used CHO cell system without metabolic activation,
they obtained a negative result (Kato et al., 2007). However, Kato
et al. synchronised the cultures to evaluate DSBs only in G1 phase.
Direct-acting genotoxic compounds in CSC may require metabolic
activation in order to generate DSBs. Other indirectly acting geno-
toxic compounds in CSC would need the cell to progress through
cell division to generate DSBs as these compounds interfere with
cell division mechanisms. Further experiments would be needed
to elucidate if the negative result was caused by the lack of meta-
bolic activation, the synchronisation or both.
Cigarette sidestream smoke (CSS) or environmental cigarette
smoke has also been reported to generate a dose- and time-related
cH2AX induction in A549 cells (Toyooka and Ibuki, 2009).
Additionally, a recent publication reported the induction of
cH2AX in A549 cells after exposure to smoke of tobacco- and nic-
otine-free cigarettes (T&N-free cigarettes) and a commercially
available control cigarette (2R4F) (Jorgensen et al., 2010). The re-
sults showed that T&N-free cigarettes produce a consistently high-
er induction of cH2AX compared to 2R4F. The results indicated
that the driver for the cH2AX increase is the tar as T&N-free ciga-
rettes produced an average of 30.9 mg of TPM per cigarette while
2R4F generate around 8.9 mg TPM per cigarette. This result con-
curs with the conclusions reported by Albino et al. that the cH2AXintensity was proportional to the estimated tar delivery (Albino
et al., 2009).
6. Conclusions
Since its discovery in 1998, the phosphorylation of H2AX to
cH2AX has been used as a tool in multiple scientiﬁc ﬁelds, from
the in vitro assessment of new drugs to a clinical biomarker.
However, the main focus of this review is to collect the efforts
of the last decade to demonstrate that the cH2AX assay could
be a potential complement to the current battery of in vitro
genotoxicity tests.
Furthermore, we have reviewed the applications of the cH2AX
assay in the in vitro evaluation of cigarette smoke, showing that
the cH2AX assay could unravel some of the DNA damaging effects
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